Healthcare Analyst Yee, along with Dr. Jason Chesney, discuss the status on IOVA launch and additional dynamics in Melanoma on an Analyst/Industry conference call to be held on June 24 at 1 pm. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOVA:
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Iovance Biotherapeutics price target lowered to $23 from $25 at JMP Securities
- Iovance Biotherapeutics call volume above normal and directionally bullish
- Iovance Biotherapeutics to Present at Upcoming Conferences and Events
- Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting